Nanobiotix is trading 6.42% up at $25.69 on October 21, with broader biotech-sector strength providing context rather than a clear company-specific catalyst.
- Shares closed October 20 at $24.14, up 14.52%.
- XBI rose 2.10% during the regular session, amid sector-wide M&A and clinical-trial optimism.
- No new company-specific announcement explaining the move was identified; the updated Phase 1 lung-cancer results report dates to September 14, not October 21.